Summit Therapeutics Inc (SMMT)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$16.03-1.05%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put SMMT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is contracting — down about 100% over the past year.
View GrowthManagement screens weak on capital allocation, earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementThis stock is volatile — it swings about 3% on a typical day and fell roughly 53% in its worst 12-month stretch.
View RiskSMMT’s central case rests on expanding clinical collaborations for ivonescimab, backed by AstraZeneca’s investment. That development must advance despite trial concerns. The latest Q2 FY2026 result beat non-GAAP EPS consensus by 26.9%. Revenue growth cannot be assessed from the available earnings history. No clean current or peer valuation multiple is available for comparison. The price is roughly in line with the growth forecast. Trial concerns could hinder ivonescimab’s Phase III development. The model puts the next-quarter miss probability at 50%. Peer multiples imply a price about 46% above where it trades. The thesis is on watch; this read is provisional.
Trailing returns as of 2026-10-30. SMMT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering SMMT (as of Oct 2026).
Based on 7 Wall Street analysts offering 12-month price targets for SMMT in the last 4 months.
Continue this research
Compare SMMT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| SMMT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put SMMT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand clinical collaborations for ivonescimab
Research partnership expands collaboration, but its early-stage scope limits direct clinical or commercial impact.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $16.03
The last 12 months of price, then the range of analyst 12-month targets from today’s $16.03.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Advance global Phase III clinical development of ivonescimab
Trial concerns could hinder Phase III development progress.
Advances: Expand clinical collaborations for ivonescimab
AstraZeneca's investment enhances clinical collaborations for ivonescimab.
Advances: Expand clinical collaborations for ivonescimab
AstraZeneca's investment supports clinical collaborations for ivonescimab.
Advances: Expand clinical collaborations for ivonescimab
AstraZeneca's $2B investment enhances growth potential for ivonescimab.
Advances: Advance global Phase III clinical development of ivonescimab
Significant progress on ivonescimab boosts growth outlook.
Advances: Advance global Phase III clinical development of ivonescimab
Positive Phase III results support ivonescimab's clinical development.
Advances: Advance global Phase III clinical development of ivonescimab
Positive Phase III data supports growth objectives for ivonescimab.